View clinical trials related to Acute Repetitive Seizures.
Filter by:This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight.
This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1